The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.
Rodríguez PC, Prada DM, Moreno E, Aira LE, Molinero C, López AM, Gómez JA, Hernández IM, Martínez JP, Reyes Y, Milera JM, Hernández MV, Torres R, Avila Y, Barrese Y, Viada C, Montero E, Hernández P.
Rodríguez PC, et al. Among authors: montero e.
Clin Exp Immunol. 2018 Feb;191(2):229-239. doi: 10.1111/cei.13061. Epub 2017 Nov 16.
Clin Exp Immunol. 2018.
PMID: 28963724
Free PMC article.
Clinical Trial.